[Cycloplatam in the treatment of patients with disseminated prostatic cancer].

A 22% response rate was achieved in clinical trials of Russian drug cycloplatam in disseminated and hormone-resistant cancer of the prostate. In 80% of cases the drug has improved quality of life of patients with prostatic cancer stage III and IV. Antitumor effect and low toxicity make cycloplatam applicable in combined therapy of prostatic cancer.

[Effect of the spread of the process and treatment on the phenotype of peripheral blood lymphocytes in patients with prostatic cancer].

A wide panel of monoclonal antibodies to differentiation antigens has been originally used to determine phenotype of peripheral blood lymphocytes in patients with prostatic cancer (PC). Patients with local PC exhibited marked lymphocytopenia existent in vertually all populations and subpopulations. In generalized PC the above changes are more pronounced.

[An experimental study of the antitumor activity of preparations in a model of prostatic cancer].

A trial of a newly developed experimental model of prostatic cancer showed its convenience in simulating clinical symptoms and response to treatment. The model is effective in the studies of anticancer drugs with various mechanisms of action with special emphasis on immunomodulators as a promising adjuvant modality.

[The antiandrogen treatment of patients with prostatic cancer and bone metastases].

In 1980-1990 the treatment for prostatic cancer in the urological department of the National Cancer Research Center was administered to 383 patients. In 208 of these the tumour disseminated to the bones. Metastases to the bones were identified by radioisotope scintigraphy of the skeletal bones, x-ray evidence being false-negative.